Systemic Lupus Erythematosus Treatment Is Commonly Done By Combining Various Steroidal and Non-Steroidal Over-The-Counter Medicines

 

Systemic lupus erythematosus treatment is easing up as the U.S. Food and Drug Administration (FDA) has been approving new drugs after a decade, considering the seriousness of Systemic Lupus erythematosus (SLE), an auto-immune disease that causes widespread internal, or extensive, inflammation throughout the body. The disease may affect several organs such as the skin, lungs, kidneys, heart, bones, brain, and veins. Scientists believe that the mechanisms involved in generating this chronic inflammation result from abnormalities in the immune system, which interferes with the body's natural ability to properly respond to infection and disease. As a result, individuals with SLE experience an exaggerated inflammatory response that triggers symptoms such as fever, swelling, and redness.

In most cases, during the systemic lupus erythematosus treatment, once doctors determine that the SLE is caused by an allergic reaction, they will recommend treating the symptoms. However, treatment options vary greatly depending on the severity of the condition. In extremely rare cases, doctors may recommend surgery, steroids, or other prescription medications for systemic lupus erythematosus treatment. In most cases, however, standard medications such as moisturizers, oral anti-fungal medicines, antihistamines, and other over-the-counter drugs are used. In these cases, doctors may also recommend an allergy test or blood tests to identify the specific allergen or immunoglobulin, which may help to determine if the condition is triggered by allergens.

Systemic lupus affects millions of people in the U.S., yet most of them do not receive regular medical checkups. Since the symptoms can present themselves in a variety of ways, many patients mistakenly believe that they are simply beginning to experience "allergy" symptoms.  Systemic lupus erythematosus treatments are mainly done with immunosuppressive drugs that restart the activity of the immune system. According to the Lupus Foundation of America, antimalarial such as Plaquenil and Aralen are given to lupus patients as an alternative to steroid medicines. However, these drugs take more time to act than steroid medicines. Such scenario has prompted R&D of new and effective drugs for the treatment of SLE. For instance, in 2019, the U.S. FDA approved Benlysta (belimumab), an intravenous drug, for the treatment of SLE in children.